Kura Oncology, Inc. (KURA)
Fuera de horario:
Kura Oncology, Inc.
12730 High Bluff Drive
Suite 400
San Diego, CA 92130
United States
858 500 8800
https://kuraoncology.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 142
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, CEO & President | 1.22M | N/D | 1969 |
| Ms. Kathleen Ford | Chief Operating Officer | 824.95k | N/D | 1947 |
| Ms. Teresa Brophy Bair Esq., J.D. | Chief Legal Officer & Corporate Secretary | 705.38k | N/D | 1971 |
| Dr. Stephen Dale M.D. | Chief Medical Officer | 855.3k | N/D | 1972 |
| Mr. Thomas Doyle | Senior Vice President of Finance & Accounting | N/D | N/D | 1971 |
| Mr. Pete De Spain | Executive Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing & Supply Chain | N/D | N/D | N/D |
| Ms. Maureen Clancy M.B.A. | VP and Global Head of Program Leadership & Project Management | N/D | N/D | N/D |
| Dr. Mollie Leoni M.D. | Executive Vice President of Clinical Development | N/D | N/D | N/D |
| Mr. Brian T. Powl M.B.A., M.S. | Chief Commercial Officer | N/D | N/D | 1974 |
Descripción
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Kura Oncology, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 4; Junta: 8; Derechos del accionista: 8; Compensación: 8.
